Berlin, Germany – February 26, 2026 – In recognition of World Rare Disease Day, Ipsen Korea hosted a thought-provoking discussion on February 25th, spotlighting the challenges faced by individuals living with rare liver diseases. The event, held at the company’s headquarters, focused on Primary Biliary Cholangitis (PBC) and Biliary Atresia, highlighting the urgent demand for increased awareness, improved diagnostics, and enhanced patient care pathways. The discussion underscored the often-overlooked impact these conditions have on patients and their families.
Rare diseases, affecting an estimated 300 million people worldwide, often present significant hurdles in diagnosis and treatment. The National Organization for Rare Disorders (NORD) defines a rare disease as one affecting fewer than 200,000 people in the United States. PBC, a chronic liver disease that slowly damages the bile ducts, and Biliary Atresia, a condition in infants where the bile ducts outside the liver do not develop normally, fall into this category, presenting unique challenges for both patients and healthcare providers. The Ipsen Korea event aimed to address some of these critical issues within the Korean healthcare landscape.
Addressing the PBC Treatment Gap in South Korea
Ipsen Korea’s event specifically highlighted the treatment gap for PBC in South Korea. According to Ipsen Korea’s Medical Director for Rare Diseases, Kwon Gu-young, a key obstacle is a lack of awareness among medical professionals. This often leads to delayed diagnoses, limited treatment options, and a lack of comprehensive monitoring systems for patients. “PBC requires early diagnosis and long-term management, but in Korea, a lack of awareness leads to diagnostic delays, limited treatment options, and a lack of monitoring systems,” Kwon stated during the event. Ipsen Korea plans to prioritize raising awareness of PBC this year through medical professional education, data-driven approaches, and strengthened collaboration with patient advocacy groups.
The complexities of PBC extend beyond diagnosis. Effective management requires ongoing monitoring of liver function and potential complications. Currently, access to specialized care and consistent monitoring can be inconsistent across South Korea, creating disparities in patient outcomes. The company’s commitment to improving these systems is a crucial step towards ensuring equitable access to care for all PBC patients.
The Critical Transition of Care for Biliary Atresia Patients
The event also addressed the often-overlooked challenges faced by children diagnosed with Biliary Atresia as they transition into adulthood. While surgical success rates for infants with Biliary Atresia have improved significantly, a critical gap exists in the healthcare system regarding the transition to adult care. Bang Hyun-jin, Secretary-General of the Korean Rare and Intractable Diseases Association, emphasized this point. “Although surgical success rates are high in children, there is no transition system to adult care, leaving patients facing a dangerous gap,” Bang explained. This lack of a seamless transition can lead to disruptions in care, increased risk of complications, and a diminished quality of life for these young adults.
The need for a continuous care pathway, extending from pediatric to adult specialists, is paramount. Establishing standardized protocols and dedicated multidisciplinary teams is essential to ensure these patients receive the ongoing support and monitoring they require throughout their lives. The Korean Rare and Intractable Diseases Association is advocating for the development of such a system, recognizing it as a critical unmet need.
The Patient Perspective: A Family’s Journey with PFIC
The Ipsen Korea event also provided a platform for patients and their families to share their experiences. Kim Ji-soo, representative of the PFIC Patient Association, poignantly described the profound impact of Progressive Familial Intrahepatic Cholestasis (PFIC) not only on the affected child but on the entire family. Kim highlighted the daily struggles with itching, sleep disturbances, and nutritional challenges, as well as the emotional toll of isolation. PFIC is a group of inherited disorders that affect the liver’s ability to transport bile, leading to a buildup of toxic substances in the body. The PFIC Foundation provides resources and support for families affected by these conditions.
The experiences shared by Kim Ji-soo underscore the importance of holistic care that addresses not only the physical symptoms of these rare liver diseases but also the psychological and social needs of patients and their families. Support groups, counseling services, and access to information are vital components of a comprehensive care plan.
Ipsen Korea’s Commitment to Rare Disease Awareness
The World Rare Disease Day event represents a significant step in Ipsen Korea’s commitment to addressing the challenges faced by individuals with rare liver diseases. Led by CEO Yang Mi-sun, the company is actively working to raise awareness, improve diagnostic capabilities, and advocate for better patient care pathways. The company’s focus on collaboration with patient advocacy groups, such as the Korean Rare and Intractable Diseases Association, is crucial to ensuring that the voices of patients are heard and that their needs are met.
Ipsen Korea’s initiatives align with a growing global movement to prioritize rare disease research and development. Increased investment in research is essential to uncover new treatments and ultimately find cures for these debilitating conditions. The company’s commitment to data-driven approaches and medical professional education will play a vital role in advancing the understanding and management of rare liver diseases in South Korea.
Looking Ahead: The Need for Continued Collaboration
The discussions at the Ipsen Korea event highlighted the complex interplay of factors contributing to the challenges faced by individuals with rare liver diseases. Addressing these challenges requires a collaborative effort involving healthcare providers, researchers, patient advocacy groups, and pharmaceutical companies. Continued dialogue, data sharing, and a commitment to patient-centered care are essential to improving the lives of those affected by these conditions.
The event served as a powerful reminder that rare diseases are not rare to those who live with them. By raising awareness, fostering collaboration, and prioritizing research, we can function towards a future where all patients, regardless of the rarity of their condition, have access to the care and support they deserve.
The next step in addressing these issues will be the implementation of Ipsen Korea’s planned initiatives, including medical professional education programs and strengthened partnerships with patient organizations. Further updates on these efforts are expected in the coming months. Readers are encouraged to share their thoughts and experiences in the comments section below.